Ginkgo Bioworks Holdings (DNA) Non-Current Deffered Revenue (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Non-Current Deffered Revenue data on file, last reported at $77.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 3.09% year-over-year to $77.9 million; the trailing twelve-month figure through Mar 2026 stood at $77.9 million (down 3.09% YoY), and the FY2025 full-year result was $75.2 million, down 23.89% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $77.9 million, up from $75.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $179.9 million in Q2 2023 and bottomed at $20.2 million in Q2 2022.
• The 5-year median for Non-Current Deffered Revenue is $150.6 million (2022), against an average of $123.7 million.
• Peak annual rise in Non-Current Deffered Revenue reached 832.29% in 2022, while the deepest fall reached 66.52% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $174.8 million in 2022, then retreated by 9.56% to $158.1 million in 2023, then plunged by 37.5% to $98.8 million in 2024, then fell by 23.89% to $75.2 million in 2025, then climbed by 3.61% to $77.9 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $77.9 million (Q1 2026), $75.2 million (Q4 2025), and $74.1 million (Q3 2025), per Business Quant data.

Peer Comparison